HtmlToText
inserm transfert initiative [paid] -- [paid] -- -- about us team portfolio shareholders news contact “advance innovative solutions to improve patients’ lives” “act as a major link between academic institutions, such as inserm, and the healthcare industry” “support scientific research to generate breakthrough products“ “work hands-on with management teams to develop successful companies” inserm transfert initiative (iti) is a french investment firm, based in paris, investing in early-stage life sciences companies. we focus on companies working on breakthrough innovations with the potential to become therapeutic solutions that will benefit society key facts events €40m under management focusing on french seed investment opportunities fully dedicated to healthcare including therapeutics, medical devices and diagnostics investment range: €1m - €3m team of experienced investor professionals invested in over 25 companies since 2005 strong connections with french public research institutes about us our story investment approach our story inserm transfert initiative (iti) was created under the initiative of inserm , the french national institute of health and medical research. inserm is a biomedical and public health research institution with nearly 15,000 researchers, engineers, technicians and post-doctoral students as well as over 300 laboratories. it is the number one academic and clinical research organisation dedicated to human health in europe. in 2005, inserm give inserm transfert — the inserm private subsidiary for scientific tech-transfer — responsibility to establish a new fund, iti, with the aim of creating a complete ecosystem around academic research institutions and addressing the need to finance early-stage life sciences companies. together with inserm transfert, 3 investment funds - bpi france, sofinnova partners and ventech - supported iti’s inception. in 2011, iti raised €35.5 million from inserm transfert, bpi france (through the “fonds national d’amorçage” ) and 10 pharmaceutical companies, making it one of the largest french life sciences seed investment funds. since september 2017, inserm transfert initiative is managed by sofimac innovation. iti has developed a strong ecosystem of close partners, including: academic institutions: inserm , cnrs , pasteur institute and other members of aviesan , the french national alliance for life sciences and health, pharmaceutical and biotech companies, leading venture capital firms. these strong connections with public and private partners will facilitate finding, seeding and growing our portfolio companies. investment approach inserm transfert initiative (iti) invests in innovative early-stage life science companies and notably spin-offs from top tier french academic research centers. iti provides financing to french start-up companies in the fields of biotechnology/biopharmaceuticals, medical devices and diagnostics. we seek out truly innovative opportunities, which target unmet medical needs, combined with strong intellectual property. at iti, we are attentive to companies that develop new approaches and breakthrough therapeutics with the potential to improve patients’ lives. iti presently brings up to €3 million equity financing per company throughout their development. investment process the assessment of investment opportunities starts with a first review of the project to see whether it matches iti’s investment criteria. secondly, iti’s management team interacts with the company’s management to better understand the scientific aspects, the strategy and the financing needs. next, iti’s team investigates further the investment possibilities and conducts an in-depth due diligence. due diligences are supported by experts from academic research, clinical practice and the life sciences industry. finally, when the due diligence is positive and the structure of the investment is defined, the company presents the opportunity to iti’s scientific advisory committee who validates the scientific approach of the investment. in most cases, iti representatives sit on the board of directors of portfolio companies. we are committed to working hands-on with the management team to develop the company and build value. through our active involvement, we provide companies with operational, financial and strategic guidance giving each of our investments optimal conditions for success. team management team shareholders representatives management team françois thomas, m.d., ph.d–p. president & managing partner françois thomas has more than 25 years of experience in the life sciences sector. before becoming manager partner inserm transfert initiative in 2014, he held management positions at ipsen (vp clinical development and cmo) and genset (vp licensing and pharmacogenomics). in 2002, françois became partner at atlas venture and in 2006 he was responsible for healthcare corporate finance at the bank bryan garnier. most recently, he was ceo of cytheris, a private biotech company. françois has been a board member of several biotech companies such as eurogentec ymb and gamamabs, as well as representative of atlas and iti in over 20 boards. in addition, in 1995 françois founded a consultancy company called bioserve ltd. françois is medical oncologist, a former assistant professor at the gustave roussy institute, and holds a ph. d in molecular oncology and an mba from mit (boston). jean-briac lesne, pharm.d. associate, pharm.d. jean-briac lesne started his professional career in the life sciences venture capital team of omnes capital. afterwards, he worked for hyperion cd, an m&a and licensing advisory company dedicated to life sciences industries. in early 2015, he joined the management team of inserm transfert initiative as analyst. jean-briac holds a pharm.d. from rennes university and graduated from escp-europe business school. shareholders representatives pascale augé jean-louis gantmacher frank kalkbrenner benjamin paternot anne germain dominique blazy kate rogers frédéric scaerou tibor papp barbara dalton emmanuelle cordano benjamin mery romain durand no result... portfolio current portfolio recently exited companies current portfolio aav-based gene therapy for genetic diseases including friedreich’s ataxia (cardiomyopathy) cannabinoid receptor antagonist therapies for central nervous system disorders robotized systems for transcranial magnetic stimulation (tms) super-resolution modules for optical microscopes modulation of dna repair to sensitize tumors to chemo- and radio-therapy monoclonal antibody acting on co-stimulation of t cells for autoimmunity and transplantation treatments targeting intracellular targets to control viral replication non-viral gene therapy for ocular diseases genomic services development of oxygen-carriers from a marine organism new drug targets for the treatment of inflammatory bowel disease therapies for acute inflammatory processes in critical care setting monoclonal antibodies for cancer small molecule for inner ear disorders (vestibular and/or cochlear disorders) detection and analysis of circulating tumor cells second generation vaccines to prevent meningitis new class of inhibitors for the treatment of autoimmune diseases treatment for rare forms of dwarfism such as achondroplasia vaccines based on an improved peptide technology focusing on cancer indications recently exited companies sensorion sensorion completed its initial public offering on the alternext market in paris in april 2015. the company successfully raised €8.2 million (4.54 euros per share). the biotech is specialized in the development of small molecule candidates for inner ear disorders (vestibular and/or cochlear disorders). iti invested in the company in 2009. laurent nguyen , ceo of sensorion, comments: “ on behalf of the entire company, i would like to thank all of our shareholders, both historical and new, who have chosen to support our innovative project to become a major player in the medical t
Informations Whois
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
%%
%% This is the AFNIC Whois server.
%%
%% complete date format : DD/MM/YYYY
%% short date format : DD/MM
%% version : FRNIC-2.5
%%
%% Rights restricted by copyright.
%% See https://www.afnic.fr/en/products-and-services/services/whois/whois-special-notice/
%%
%% Use '-h' option to obtain more information about this service.
%%
%% [2600:3c03:0000:0000:f03c:91ff:feae:779d REQUEST] >> it-initiative.fr
%%
%% RL Net [##########] - RL IP [#########.]
%%
domain: it-initiative.fr
status: ACTIVE
hold: NO
holder-c: INSE6-FRNIC
admin-c: LV2783-FRNIC
tech-c: GRST1-FRNIC
tech-c: PL1721-FRNIC
tech-c: JM1423-FRNIC
zone-c: NFC1-FRNIC
nsl-id: NSL59387-FRNIC
registrar: GIP RENATER
Expiry Date: 01/11/2017
created: 07/06/2007
last-update: 27/08/2017
source: FRNIC
ns-list: NSL59387-FRNIC
nserver: ns1.inserm.fr [195.98.252.130]
nserver: ns2.inserm.fr [193.52.143.131]
nserver: ns3.inserm.fr
source: FRNIC
registrar: GIP RENATER
type: Isp Option 1
address: 23-25 Rue Daviel
address: PARIS
country: FR
phone: +33 1 53 94 20 30
fax-no: +33 1 53 94 20 31
e-mail: domaine@renater.fr
website: http://www.renater.fr
anonymous: NO
registered: 01/01/1998
source: FRNIC
nic-hdl: INSE6-FRNIC
type: ORGANIZATION
contact: INST NAT SANTE ET LA RECHERCHE MEDICALE
address: INSERM
address: Dsi / Se2I 101 rue de Tolbiac
address: 75654 Paris
country: FR
phone: +33 1 44 23 60 00
e-mail: domain.dsi@inserm.fr
registrar: GIP RENATER
changed: 27/08/2017 nic@nic.fr
anonymous: NO
obsoleted: NO
source: FRNIC
nic-hdl: LV2783-FRNIC
type: PERSON
contact: Laurent Vigneron
address: INSERM
address: Dsi
address: 16, avenue Paul Vaillant couturier
address: Bât Laplace
address: 94807 Villejuif
country: FR
phone: +33 1 44 23 60 25
e-mail: directeur.dsi@inserm.fr
registrar: GIP RENATER
changed: 19/12/2012 nic@nic.fr
anonymous: NO
obsoleted: NO
source: FRNIC
nic-hdl: GRST1-FRNIC
type: PERSON
contact: Gip Renater Support Technique Dns
address: GIP RENATER
address: 23-25, rue Daviel
address: 75013 Paris
country: FR
phone: +33 1 53 94 20 40
e-mail: support@renater.fr
registrar: GIP RENATER
changed: 21/07/2015 nic@nic.fr
anonymous: NO
obsoleted: NO
source: FRNIC
nic-hdl: PL1721-FRNIC
type: PERSON
contact: Patrick Lerouge
address: INSERM - DSI
address: 13, rue Watt
address: 75013 Paris
country: FR
phone: +33 1 82 53 34 10
e-mail: resnat.dsi@inserm.fr
registrar: GIP RENATER
changed: 03/08/2017 nic@nic.fr
anonymous: NO
obsoleted: NO
source: FRNIC
nic-hdl: JM1423-FRNIC
type: PERSON
contact: Julio Martins
address: INSERM DSI
address: 13, rue Watt
address: 75013 Paris
country: FR
phone: +33 1 82 53 34 11
e-mail: julio.martins@inserm.fr
registrar: GIP RENATER
changed: 22/09/2015 nic@nic.fr
anonymous: NO
obsoleted: NO
source: FRNIC
REFERRER http://www.nic.fr
REGISTRAR AFNIC
SERVERS
SERVER fr.whois-servers.net
ARGS it-initiative.fr
PORT 43
TYPE domain
RegrInfo
DISCLAIMER
%
% This is the AFNIC Whois server.
%
% complete date format : DD/MM/YYYY
% short date format : DD/MM
% version : FRNIC-2.5
%
% Rights restricted by copyright.
% See https://www.afnic.fr/en/products-and-services/services/whois/whois-special-notice/
%
% Use '-h' option to obtain more information about this service.
%
% [2600:3c03:0000:0000:f03c:91ff:feae:779d REQUEST] >> it-initiative.fr
%
% RL Net [##########] - RL IP [#########.]
%
REGISTERED yes
ADMIN
HANDLE LV2783-FRNIC
TYPE PERSON
CONTACT Laurent Vigneron
ADDRESS
INSERM
Dsi
16, avenue Paul Vaillant couturier
Bât Laplace
94807 Villejuif
COUNTRY FR
PHONE +33 1 44 23 60 25
EMAIL directeur.dsi@inserm.fr
SPONSOR GIP RENATER
CHANGED 2012-12-19
ANONYMOUS NO
OBSOLETED NO
SOURCE FRNIC
TECH
HANDLE JM1423-FRNIC
TYPE PERSON
CONTACT Julio Martins
ADDRESS
INSERM DSI
13, rue Watt
75013 Paris
COUNTRY FR
PHONE +33 1 82 53 34 11
EMAIL julio.martins@inserm.fr
SPONSOR GIP RENATER
CHANGED 2015-09-22
ANONYMOUS NO
OBSOLETED NO
SOURCE FRNIC
OWNER
HANDLE INSE6-FRNIC
TYPE ORGANIZATION
CONTACT INST NAT SANTE ET LA RECHERCHE MEDICALE
ADDRESS
INSERM
Dsi / Se2I 101 rue de Tolbiac
75654 Paris
COUNTRY FR
PHONE +33 1 44 23 60 00
EMAIL domain.dsi@inserm.fr
SPONSOR GIP RENATER
CHANGED 2017-08-27
ANONYMOUS NO
OBSOLETED NO
SOURCE FRNIC
DOMAIN
STATUS ACTIVE
HOLD NO
SPONSOR GIP RENATER
EXPIRY DATE 01/11/2017
CREATED 2007-06-07
CHANGED 2017-08-27
SOURCE FRNIC
HANDLE NSL59387-FRNIC
NSERVER
NS1.INSERM.FR 195.98.252.130
NS2.INSERM.FR 193.52.143.131
NS3.INSERM.FR 193.52.0.7
NAME it-initiative.fr
Go to top
it-initiative.fr rapport :
Visitez le site